middle.news
Imagion Biosystems Advances with Positive FDA Feedback on HER2 Breast Cancer Trial
9:42am on Thursday 10th of July, 2025 AEST
•
Healthcare
Read Story
Imagion Biosystems Advances with Positive FDA Feedback on HER2 Breast Cancer Trial
9:42am on Thursday 10th of July, 2025 AEST
Key Points
Positive FDA feedback on MagSense® HER2 imaging agent
Phase 2 clinical trial planned for HER2 breast cancer in the U.S.
IND application submission expected in Q3 2025
Upcoming in-person FDA meeting to finalize trial approval process
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imagion Biosystems (ASX:IBX)
OPEN ARTICLE